The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“practice guidelines increasingly recognize the prevention of ischemic events as a key management priority.5,6”
In the citing paper
“However, subsequent trials that specifically examined the role of a blood pressure lowering strategy to <130 mm Hg in patients with T2DM and hypertension found no substantive benefit of intensive blood pressure control in reducing the risk of coronary events, although there was evidence for decreased risk of stroke.5,66–69”
In the citing paper
“As such, while all patients with T2DM and CAD certainly benefit from a blood pressure of <140/90 mm Hg,5,63–66,76”
In the citing paper
“ACE inhibitors/ARBs reduce the progression of kidney disease in patients with albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g)5 and reduce the risk of both incident and recurrent atherosclerotic ischemic events.79,80”
In the citing paper
“Furthermore, fibrates or fish oil would be indicated when triglycerides are very high (>500 mg/dL) to reduce the risk of pancreatitis.5”
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Sacks, F. M., Svetkey, L. P., Vollmer, W. M., Appel, L. J., Bray, G. A., Harsha, D., Obarzanek, E., Conlin, P. R., Miller, E. R., Simons-Morton, D. G., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101043440101 · Cited by 5,638 · cited 1×
“ducing excess body weight through caloric restriction, restricting sodium intake (,2,300 mg/day), increasing consumption of fruits and vegetables (8–10 servings per day) and low-fat dairy products (2–3 servings per day), avoiding excessive alcohol consumption (no more than 2 servings per day in men and no more than 1…”
BackgroundIntensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Optimal Medical Therapy with or without PCI for Stable Coronary Disease
Boden, W. E., O'Rourke, R. A., Teo, K. K., Hartigan, P. M., Maron, D. J., Kostuk, W. J., Knudtson, M., Dada, M., Casperson, P., Harris, C. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070829 · Cited by 4,699
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., & Rahimi, K. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01225-8 · Cited by 3,755 · cited 1×
“failure but have not been shown to reducemortality as blood pressure-lowering agents in the absence of these conditions (23,57).”
BackgroundEstruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800389 · Cited by 3,616
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Economic Costs of Diabetes in the U.S. in 2017
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dci18-0007 · Cited by 2,528
Self-citationAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Platelet Activation and Atherothrombosis
Davì, G., & Patrono, C. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071014 · Cited by 2,135
Role of diabetes in congestive heart failure: The Framingham study
Kannel, W. B., Hjortland, M., & Castelli, W. P. (1974) · The American Journal of Cardiology · doi:10.1016/0002-9149(74)90089-7 · Cited by 2,090
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081 · cited 3×
“(78,86), including subgroups that varied with respect to age andother risk factors.”
A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805796 · Cited by 1,939 · cited 1×
“patients should already be receiving intensive medical therapydan approach that provides similar benefit as invasive revascularization (141,142).”
BackgroundStatins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623
Williams, B., MacDonald, T. M., Morant, S., Webb, D. J., Sever, P., McInnes, G., Ford, I., Cruickshank, J. K., Caulfield, M. J., Salsbury, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00257-3 · Cited by 1,308
Effects of aspirin for primary prevention in persons with diabetes mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804988 · Cited by 1,200
Combined angiotensin inhibition for the treatment of diabetic nephropathy
Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303154 · Cited by 1,169
Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly
McNeil, J. J., Wolfe, R., Woods, R. L., Tonkin, A. M., Donnan, G. A., Nelson, M. R., Reid, C. M., Lockery, J. E., Kirpach, B., Storey, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805819 · Cited by 1,139 · cited 3×
“Two other large randomized trials of aspirin for primary prevention, in patients without diabetes (ARRIVE [Aspirin to Reduce Risk of Initial Vascular Events]) (122) and in the elderly (ASPREE [Aspirin in Reducing Events in the Elderly]) (123), including 11% with diabetes, found no benefit of aspirin on the primary eff…”
BackgroundAngiotensin-converting-enzyme inhibition in stable coronary artery disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa042739 · Cited by 1,123
Fixed-Dose Combinations Improve Medication Compliance: A Meta-Analysis
Bangalore, S., Kamalakkannan, G., Parkar, S., & Messerli, F. H. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.08.033 · Cited by 1,075
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus
Buse, J. B., Ginsberg, H. N., Bakris, G. L., Clark, N. G., Costa, F., Eckel, R., Fonseca, V., Gerstein, H. C., Grundy, S., Nesto, R. W., et al. (2007) · Diabetes Care · doi:10.2337/dc07-9917 · Cited by 1,055
Irgens, H. U., Roberts, J. M., Reisæter, L., Irgens, L. M., & Lie, R. T. (2001) · BMJ · doi:10.1136/bmj.323.7323.1213 · Cited by 1,040
Sega, R., Facchetti, R., Bombelli, M., Cesana, G., Corrao, G., Grassi, G., & Mancia, G. (2005) · Circulation · doi:10.1161/01.cir.0000160923.04524.5b · Cited by 1,009
Goldberg, R. B., Mellies, M. J., Sacks, F. M., Moyé, L. A., Howard, B. V., Howard, W. J., Davis, B. R., Cole, T. G., Pfeffer, M. A., & Braunwald, E. (1998) · Circulation · doi:10.1161/01.cir.98.23.2513 · Cited by 986
Xie, X., Atkins, E., Lv, J., Bennett, A., Neal, B., Ninomiya, T., Woodward, M., MacMahon, S., Turnbull, F., Hillis, G. S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00805-3 · Cited by 980
Achievement of Goals in U.S. Diabetes Care, 1999–2010
Ali, M. K., Bullard, K. M., Saaddine, J. B., Cowie, C. C., Imperatore, G., & Gregg, E. W. (2013) · New England Journal of Medicine · doi:10.1056/nejmsa1213829 · Cited by 979
Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., Lee, R., Bancroft, J., MacEwan, S., Shepherd, J., et al. (2008) · BMJ · doi:10.1136/bmj.a1840 · Cited by 977
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887
Gaziano, J. M., Brotons, C., Coppolecchia, R., Cricelli, C., Darius, H., Gorelick, P. B., Howard, G., Pearson, T. A., Rothwell, P. M., Ruilope, L. M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31924-x · Cited by 883
Blood Pressure Lowering in Type 2 Diabetes: A Systematic Review and Meta-analysis
Emdin, C. A., Rahimi, K., Neal, B., Callender, T., Perkovic, V., & Patel, A. (2015) · JAMA · doi:10.1001/jama.2014.18574 · Cited by 854
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L. A., Dans, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600176 · Cited by 848
Ridker, P. M., Pradhan, A., MacFadyen, J. G., Libby, P., & Glynn, R. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61190-8 · Cited by 816
Young, L. H., Wackers, F. J. T., Chyun, D. A., Davey, J. A., Barrett, E. J., Taillefer, R., Heller, G. V., Iskandrian, A. E., Wittlin, S. D., Filipchuk, N., et al. (2009) · JAMA · doi:10.1001/jama.2009.476 · Cited by 809 · cited 2×
“However, a randomized observational trial demonstrated no clinical benefit to routine screening of asymptomatic patients with type 2 diabetes and normal ECGs (147).”
BackgroundPeters, S. A. E., Huxley, R. R., & Woodward, M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60040-4 · Cited by 805
Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects
Wackers, F. J. T., Young, L. H., Inzucchi, S. E., Chyun, D. A., Davey, J. A., Barrett, E. J., Taillefer, R., Wittlin, S. D., Heller, G. V., Filipchuk, N., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1954 · Cited by 791
Zannad, F., Cannon, C. P., Cushman, W. C., Bakris, G. L., Menon, V., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., Wilson, C., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62225-x · Cited by 757
Diabetes and hypertension: a position statement by the American Diabetes Association
de Boer, I. H., Bangalore, S., Benetos, A., Davis, A. M., Michos, E. D., Muntner, P., Rossing, P., Zoungas, S., & Bakris, G. (2017) · Diabetes Care · doi:10.2337/dci17-0026 · Cited by 714
Bakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2015) · JAMA · doi:10.1001/jama.2015.10081 · Cited by 708
Antihypertensive drug therapy for mild to moderate hypertension during pregnancy
Abalos, E., Duley, L., & Steyn, D. W. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002252.pub3 · Cited by 705
Peters, S. A. E., Huxley, R. R., & Woodward, M. (2014) · Diabetologia · doi:10.1007/s00125-014-3260-6 · Cited by 701
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes
Zoungas, S., Chalmers, J., Neal, B., Billot, L., Li, Q., Hirakawa, Y., Arima, H., Monaghan, H., Joshi, R., Colagiuri, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407963 · Cited by 626
(2014) · The Lancet · doi:10.1016/s0140-6736(14)61212-5 · Cited by 623
Prognostic value of coronary artery calcium screening in subjects with and without diabetes
Raggi, P., Shaw, L. J., Berman, D. S., & Callister, T. Q. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.09.068 · Cited by 608
Validation of the Atherosclerotic Cardiovascular Disease Pooled Cohort Risk Equations
Muntner, P., Colantonio, L. D., Cushman, M., Goff, D. C., Howard, G., Howard, V. J., Kissela, B., Levitan, E. B., Lloyd-Jones, D. M., & Safford, M. M. (2014) · JAMA · doi:10.1001/jama.2014.2630 · Cited by 603
Sabatine, M. S., Leiter, L. A., Wiviott, S. D., Giugliano, R. P., Deedwania, P., De Ferrari, G. M., Murphy, S. A., Kuder, J. F., Gouni-Berthold, I., Lewis, B. S., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30313-3 · Cited by 603
Atenolol in hypertension: is it a wise choice?
Carlberg, B., Samuelsson, O., & Lindholm, L. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17355-8 · Cited by 562
Knopp, R. H., d’Emden, M., Smilde, J. G., Pocock, S. J., & on behalf of the ASPEN Study Group (2006) · Diabetes Care · doi:10.2337/dc05-2415 · Cited by 550
Shepherd, J., Barter, P., Carmena, R., Deedwania, P., Fruchart, J.-C., Haffner, S., Hsia, J., Breazna, A., LaRosa, J., Grundy, S., et al. (2006) · Diabetes Care · doi:10.2337/dc05-2465 · Cited by 525
de Ferranti, S. D., de Boer, I. H., Fonseca, V., Fox, C. S., Golden, S. H., Lavie, C. J., Magge, S. N., Marx, N., McGuire, D. K., Orchard, T. J., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000034 · Cited by 503
Cavender, M. A., Steg, P. G., Smith, S. C., Eagle, K., Ohman, E. M., Goto, S., Kuder, J., Im, K., Wilson, P. W. F., & Bhatt, D. L. (2015) · Circulation · doi:10.1161/circulationaha.114.014796 · Cited by 501
Cognitive function in a randomized trial of evolocumab
Giugliano, R. P., Mach, F., Zavitz, K., Kurtz, C., Im, K., Kanevsky, E., Schneider, J., Wang, H., Keech, A., Pedersen, T. R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701131 · Cited by 492
Primary and Secondary Prevention of Cardiovascular Disease
Vandvik, P. O., Lincoff, A. M., Gore, J. M., Gutterman, D. D., Sonnenberg, F. A., Alonso-Coello, P., Akl, E. A., Lansberg, M. G., Guyatt, G. H., & Spencer, F. A. (2012) · Chest · doi:10.1378/chest.11-2306 · Cited by 476
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Pharmacogenetic Study of Statin Therapy and Cholesterol Reduction
Chasman, D. I. (2004) · JAMA · doi:10.1001/jama.291.23.2821 · Cited by 453
Filippatos, G., Anker, S. D., Böhm, M., Gheorghiade, M., Køber, L., Krum, H., Maggioni, A. P., Ponikowski, P., Voors, A. A., Zannad, F., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw132 · Cited by 446
Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review
Campbell, C. L., Smyth, S., Montalescot, G., & Steinhubl, S. R. (2007) · JAMA · doi:10.1001/jama.297.18.2018 · Cited by 444
Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
Rajpathak, S. N., Kumbhani, D. J., Crandall, J., Barzilai, N., Alderman, M., & Ridker, P. M. (2009) · Diabetes Care · doi:10.2337/dc09-0738 · Cited by 439
Bangalore, S., Kumar, S., Lobach, I., & Messerli, F. H. (2011) · Circulation · doi:10.1161/circulationaha.110.016337 · Cited by 437
Giugliano, R. P., Cannon, C. P., Blazing, M. A., Nicolau, J. C., Corbalán, R., Špinar, J., Park, J.-G., White, J. A., Bohula, E. A., & Braunwald, E. (2018) · Circulation · doi:10.1161/circulationaha.117.030950 · Cited by 427
Risk of incident diabetes among patients treated with statins: population based study
Carter, A. A., Gomes, T., Camacho, X., Juurlink, D. N., Shah, B. R., & Mamdani, M. M. (2013) · BMJ · doi:10.1136/bmj.f2610 · Cited by 404
De Berardis, G., Sacco, M., Strippoli, G. F. M., Pellegrini, F., Graziano, G., Tognoni, G., & Nicolucci, A. (2009) · BMJ · doi:10.1136/bmj.b4531 · Cited by 395
Palmer, S. C., Mavridis, D., Navarese, E., Craig, J. C., Tonelli, M., Salanti, G., Wiebe, N., Ruospo, M., Wheeler, D. C., & Strippoli, G. F. M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62459-4 · Cited by 395
Anand, D. V., Lim, E., Hopkins, D., Corder, R., Shaw, L. J., Sharp, P., Lipkin, D., & Lahiri, A. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi808 · Cited by 392
Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes
Sever, P. S., Poulter, N. R., Dahlöf, B., Wedel, H., Collins, R., Beevers, G., Caulfield, M., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1151 · Cited by 390
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
Jones, P. H., & Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.08.076 · Cited by 387
Huxley, R. R., Peters, S. A. E., Mishra, G. D., & Woodward, M. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70248-7 · Cited by 383
Brunström, M., & Carlberg, B. (2016) · BMJ · doi:10.1136/bmj.i717 · Cited by 375
Mach, F., Ray, K. K., Wiklund, O., Corsini, A., Catapano, A. L., Bruckert, E., De Backer, G., Hegele, R. A., Hovingh, G. K., Jacobson, T. A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy182 · Cited by 370
Cefalu, W. T., Kaul, S., Gerstein, H. C., Holman, R. R., Zinman, B., Skyler, J. S., Green, J. B., Buse, J. B., Inzucchi, S. E., Leiter, L. A., et al. (2018) · Diabetes Care · doi:10.2337/dci17-0057 · Cited by 363
Heart failure with preserved ejection fraction: from mechanisms to therapies
Lam, C. S. P., Voors, A. A., de Boer, R. A., Solomon, S. D., & van Veldhuisen, D. J. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy301 · Cited by 355
Eckel, R. H., Jakicic, J. M., Ard, J. D., Jesus, J. M. D., Miller, N. H., Hubbard, V. S., Lee, I.-M. M., Lichtenstein, A. H., Loria, C. M., Millen, B. E., et al. (2014) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · Cited by 354
Rothwell, P. M., Cook, N. R., Gaziano, J. M., Price, J. F., Belch, J. F. F., Roncaglioni, M. C., Morimoto, T., & Mehta, Z. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31133-4 · Cited by 353
Statins for the primary prevention of cardiovascular disease
Ebrahim, S., Taylor, F. C., & Brindle, P. (2014) · BMJ · doi:10.1136/bmj.g280 · Cited by 333
Omboni, S., Gazzola, T., Carabelli, G., & Parati, G. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e32835ca8dd · Cited by 313
James, M. T., Grams, M. E., Woodward, M., Elley, C. R., Green, J. A., Wheeler, D. C., de Jong, P., Gansevoort, R. T., Levey, A. S., Warnock, D. G., et al. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.02.338 · Cited by 309
Pravastatin and cognitive function in the elderly. Results of the PROSPER study
Trompet, S., Vliet, P., Craen, A. J. M., Jolles, J., Buckley, B. M., Murphy, M. B., Ford, I., Macfarlane, P. W., Sattar, N., Packard, C. J., et al. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5271-7 · Cited by 291
Elkeles, R. S., Godsland, I. F., Feher, M. D., Rubens, M. B., Roughton, M., Nugara, F., Humphries, S. E., Richmond, W., Flather, M. D., & for the PREDICT Study Group (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn279 · Cited by 261
Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
Zhang, X.-L., Zhu, Q.-Q., Zhu, L., Chen, J.-Z., Chen, Q.-H., Li, G.-N., Xie, J., Kang, L.-N., & Xu, B. (2015) · BMC Medicine · doi:10.1186/s12916-015-0358-8 · Cited by 260
Margolis, K. L., O’Connor, P. J., Morgan, T. M., Buse, J. B., Cohen, R. M., Cushman, W. C., Cutler, J. A., Evans, G. W., Gerstein, H. C., Grimm, R. H., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2334 · Cited by 259
Screening for coronary artery disease in patients with diabetes
Bax, J. J., Young, L. H., Frye, R. L., Bonow, R. O., Steinberg, H. O., & Barrett, E. J. (2007) · Diabetes Care · doi:10.2337/dc07-9927 · Cited by 251
Statins and Cognitive Function: A Systematic Review
Richardson, K., Schoen, M., French, B., Umscheid, C. A., Mitchell, M. D., Arnold, S. E., Heidenreich, P. A., Rader, D. J., & deGoma, E. M. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-10-201311190-00007 · Cited by 250
Detection of Coronary Artery Disease in Asymptomatic Patients With Type 2 Diabetes Mellitus
Scognamiglio, R., Negut, C., Ramondo, A., Tiengo, A., & Avogaro, A. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.10.008 · Cited by 249
Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes
Weber, M. A., Bakris, G. L., Jamerson, K., Weir, M., Kjeldsen, S. E., Devereux, R. B., Velazquez, E. J., Dahlöf, B., Kelly, R. Y., Hua, T. A., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.046 · Cited by 244
Makani, H., Bangalore, S., Desouza, K. A., Shah, A., & Messerli, F. H. (2013) · BMJ · doi:10.1136/bmj.f360 · Cited by 244
McAllister, D. A., Read, S. H., Kerssens, J., Livingstone, S., McGurnaghan, S., Jhund, P., Petrie, J., Sattar, N., Fischbacher, C., Kristensen, S. L., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034986 · Cited by 244
Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes
Pignone, M., Alberts, M. J., Colwell, J. A., Cushman, M., Inzucchi, S. E., Mukherjee, D., Rosenson, R. S., Williams, C. D., Wilson, P. W., & Kirkman, M. S. (2010) · Diabetes Care · doi:10.2337/dc10-0555 · Cited by 242
Fitchett, D., Butler, J., van de Borne, P., Zinman, B., Lachin, J. M., Wanner, C., Woerle, H. J., Hantel, S., George, J. T., Johansen, O. E., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx511 · Cited by 242
Feldman, R. D., Zou, G. Y., Vandervoort, M. K., Wong, C. J., Nelson, S. A. E., & Feagan, B. G. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.123455 · Cited by 239
Bhatt, D. L., Bonaca, M. P., Bansilal, S., Angiolillo, D. J., Cohen, M., Storey, R. F., Im, K., Murphy, S. A., Held, P., Braunwald, E., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.529 · Cited by 216
Malik, S., Zhao, Y., Budoff, M., Nasir, K., Blumenthal, R. S., Bertoni, A. G., & Wong, N. D. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.4191 · Cited by 215
Hermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2011) · Diabetes Care · doi:10.2337/dc11-0297 · Cited by 213
Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system
Nilsson, E., Gasparini, A., Ärnlöv, J., Xu, H., Henriksson, K. M., Coresh, J., Grams, M. E., & Carrero, J. J. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.07.035 · Cited by 211
Thomopoulos, C., Parati, G., & Zanchetti, A. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001276 · Cited by 206
Pignone, M., Earnshaw, S., Tice, J. A., & Pletcher, M. J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-5-200603070-00007 · Cited by 204
Atherothrombotic risk stratification and ezetimibe for secondary prevention
Bohula, E. A., Morrow, D. A., Giugliano, R. P., Blazing, M. A., He, P., Park, J.-G., Murphy, S. A., White, J. A., Kesaniemi, Y. A., Pedersen, T. R., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.070 · Cited by 204
Webster, R., Salam, A., de Silva, H. A., Selak, V., Stepien, S., Rajapakse, S., Amarasekara, S., Amarasena, N., Billot, L., de Silva, A. P., et al. (2018) · JAMA · doi:10.1001/jama.2018.10359 · Cited by 199
Bangalore, S., Fakheri, R., Toklu, B., & Messerli, F. H. (2016) · BMJ · doi:10.1136/bmj.i438 · Cited by 183 · cited 1×
“In the absence of albuminuria, risk of progressive kidney disease is low, and ACE inhibitors and ARBs have not been found to afford superior cardioprotection when compared with thiazide-like diuretics or dihydropyridine calcium channel blockers (56).”
Bandak, G., Sang, Y., Gasparini, A., Chang, A. R., Ballew, S. H., Evans, M., Arnlov, J., Lund, L. H., Inker, L. A., Coresh, J., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005428 · Cited by 181 · cited 6×
“Therefore, serum creatinine and potassium should be monitored during treatment with an ACE inhibitor, ARB, or diuretic, particularly among patients with reduced glomerular filtration who are at increased risk of hyperkalemia and AKI (63,64,66).”
BackgroundInfluentialNeal, B., Perkovic, V., Matthews, D. R., Mahaffey, K. W., Fulcher, G., Meininger, G., Erondu, N., Desai, M., Shaw, W., Vercruysse, F., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12829 · Cited by 174
DeFilippis, A. P., Young, R., McEvoy, J. W., Michos, E. D., Sandfort, V., Kronmal, R. A., McClelland, R. L., & Blaha, M. J. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw301 · Cited by 169
Bohula, E. A., Bonaca, M. P., Braunwald, E., Aylward, P. E., Corbalan, R., De Ferrari, G. M., He, P., Lewis, B. S., Merlini, P. A., Murphy, S. A., et al. (2016) · Circulation · doi:10.1161/circulationaha.115.019861 · Cited by 168
Moriarty, P. M., Jacobson, T. A., Bruckert, E., Thompson, P. D., Guyton, J. R., Baccara-Dinet, M. T., & Gipe, D. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.09.007 · Cited by 154
Blood pressure targets for hypertension in people with diabetes mellitus
Arguedas, J. A., Leiva, V., & Wright, J. M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008277.pub2 · Cited by 151
Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis
Zhang, C., Sun, A., Zhang, P., Wu, C., Zhang, S., Fu, M., Wang, K., Zou, Y., & Ge, J. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.09.029 · Cited by 150
Kalyani, R. R., Lazo, M., Ouyang, P., Turkbey, E. B., Chevalier, K., Brancati, F. L., Becker, D. M., & Vaidya, D. M. (2013) · Diabetes Care · doi:10.2337/dc13-1755 · Cited by 143
Wackers, F. J. T., Chyun, D. A., Young, L. H., Heller, G. V., Iskandrian, A. E., Davey, J. A., Barrett, E. J., Taillefer, R., Wittlin, S. D., Filipchuk, N., et al. (2007) · Diabetes Care · doi:10.2337/dc07-1250 · Cited by 137
Beddhu, S., Greene, T., Boucher, R., Cushman, W. C., Wei, G., Stoddard, G., Ix, J. H., Chonchol, M., Kramer, H., Cheung, A. K., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30099-8 · Cited by 128
Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP
Buckley, L. F., Dixon, D. L., Wohlford, G. F., Wijesinghe, D. S., Baker, W. L., & Tassell, B. W. V. (2017) · Diabetes Care · doi:10.2337/dc17-1366 · Cited by 120
Evening versus morning dosing regimen drug therapy for hypertension
Zhao, P., Xu, P., Wan, C., & Wang, Z. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004184.pub2 · Cited by 118
Bobrie, G., Genès, N., Vaur, L., Clerson, P., Vaisse, B., Mallion, J.-M., & Chatellier, G. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.18.2205 · Cited by 117
Catalá-López, F., Macías Saint-Gerons, D., González-Bermejo, D., Rosano, G. M., Davis, B. R., Ridao, M., Zaragoza, A., Montero-Corominas, D., Tobías, A., de la Fuente-Honrubia, C., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001971 · Cited by 109
Bakris, G. L., Weir, M. R., & on behalf of the Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators (2003) · The Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2002.2041.x · Cited by 94
Hughes-Austin, J. M., Rifkin, D. E., Beben, T., Katz, R., Sarnak, M. J., Deo, R., Hoofnagle, A. N., Homma, S., Siscovick, D. S., Sotoodehnia, N., et al. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06290616 · Cited by 92
Sink, K. M., Evans, G. W., Shorr, R. I., Bates, J. T., Berlowitz, D., Conroy, M. B., Felton, D. M., Gure, T., Johnson, K. C., Kitzman, D., et al. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15236 · Cited by 92
Hadamitzky, M., Hein, F., Meyer, T., Bischoff, B., Martinoff, S., Schömig, A., & Hausleiter, J. (2010) · Diabetes Care · doi:10.2337/dc09-2104 · Cited by 90
Phillips, R. A., Xu, J., Peterson, L. E., Arnold, R. M., Diamond, J. A., & Schussheim, A. E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.074 · Cited by 88 · cited 1×
“Absolute benefit from blood pressure reduction correlated with absolute baseline cardiovascular risk in SPRINT and in earlier clinical trials conducted at higher baseline blood pressure levels (11,37).”
ResultKezerashvili, A., Marzo, K. P., & Leon, J. D. (2012) · Current Cardiology Reviews · doi:10.2174/157340312801215764 · Cited by 81
Basu, S., Sussman, J. B., Rigdon, J., Steimle, L., Denton, B. T., & Hayward, R. A. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002410 · Cited by 77
Barzilay, J. I., Davis, B. R., Bettencourt, J., Margolis, K. L., Goff, D. C., Black, H., Habib, G., Ellsworth, A., Force, R. W., Wiegmann, T., et al. (2004) · The Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2004.03216.x · Cited by 70
The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure
Bakris, G. L. (2016) · Circulation · doi:10.1161/circulationaha.116.022536 · Cited by 70
Bethel, M. A., Harrison, P., Sourij, H., Sun, Y., Tucker, L., Kennedy, I., White, S., Hill, L., Oulhaj, A., Coleman, R. L., et al. (2016) · Diabetic Medicine · doi:10.1111/dme.12828 · Cited by 61
Choi, E.-K., Chun, E. J., Choi, S.-I., Chang, S.-A., Choi, S.-H., Lim, S., Rivera, J. J., Nasir, K., Blumenthal, R. S., Jang, H.-C., et al. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.05.026 · Cited by 57
de Boer, I. H., Bakris, G., & Cannon, C. P. (2018) · JAMA · doi:10.1001/jama.2018.0642 · Cited by 54
In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes
Zaccardi, F., Rizzi, A., Petrucci, G., Ciaffardini, F., Tanese, L., Pagliaccia, F., Cavalca, V., Ciminello, A., Habib, A., Squellerio, I., et al. (2016) · Diabetes · doi:10.2337/db15-0936 · Cited by 53
Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52
Meek, C., Wierzbicki, A. S., Jewkes, C., Twomey, P. J., Crook, M. A., Jones, A., & Viljoen, A. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.657302 · Cited by 52
Larsen, S. B., Grove, E. L., Neergaard‐Petersen, S., Würtz, M., Hvas, A., & Kristensen, S. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126767 · Cited by 51
Renal denervation for the treatment of resistant hypertension: review and clinical perspective
Iliescu, R., Lohmeier, T. E., Tudorancea, I., Laffin, L., & Bakris, G. L. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00246.2015 · Cited by 50
Evening‐ versus morning‐dosing‐regimen drug therapy for hypertension
(2011) · Prescriber · doi:10.1002/psb.830 · Cited by 48
Brouwer, T. F., Vehmeijer, J. T., Kalkman, D. N., Berger, W. R., van den Born, B.-J. H., Peters, R. J., & Knops, R. E. (2018) · Diabetes Care · doi:10.2337/dc17-1722 · Cited by 44
Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease
Mora, S., Ames, J. M., & Manson, J. E. (2016) · JAMA · doi:10.1001/jama.2016.8362 · Cited by 41
Use of diuretics during pregnancy.
Al-Balas, M., Bozzo, P., & Einarson, A. (2009) · PubMed Central · Cited by 35
Mineralocorticoid Receptor Blockade in Chronic Kidney Disease
Bomback, A. S., & Klemmer, P. J. (2012) · Blood Purification · doi:10.1159/000334161 · Cited by 29
Dimitriu‐Leen, A. C., Scholte, A. J. H. A., van Rosendael, A. R., van den Hoogen, I. J., Kharagjitsingh, A. V., Wolterbeek, R., Knuuti, J. M., Kroft, L. J. M., Delgado, V., Jukema, J. W., et al. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.12.023 · Cited by 25
Reevaluating the Evidence for Blood Pressure Targets in Type 2 Diabetes
Lamprea-Montealegre, J. A., & de Boer, I. H. (2018) · Diabetes Care · doi:10.2337/dci17-0063 · Cited by 12
Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis
Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · JAMA · doi:10.1001/jama.298.10.1189 · Cited by 5
Research works printed but not linked: 2
- American College of Obstetricians and Gynecologists’, 2013, Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy, Obstet Gynecol, 122, 1122
- Fitchett, 2017, Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME trial, Eur Heart J, 39, 363, 10.1093/eurheartj/ehx511 · DOI · Paper page
Cited by
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Lopaschuk, G. D., & Verma, S. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.02.004 · Cited by 894
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Ma, C.-X., Ma, X.-N., Guan, C.-H., Li, Y.-D., Mauricio, D., & Fu, S.-B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01516-6 · Cited by 464
ACC/AHA Versus ESC/ESH on Hypertension Guidelines
Bakris, G., Ali, W., & Parati, G. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.507 · Cited by 319
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-12-07
- Volume
- 42
- Issue
- Supplement_1
- Pages
- S103-S123
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4213222556
- Semantic Scholar
- b0a37d21ada65be89484f4b750bf45f281a7f7c5
- Cited by
- 471
- References
- 172
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 20 · 2023: 35 · 2022: 65 · 2021: 84 · 2020: 134 · 2019: 109
- FWCI
- 12.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- cardiovascular disease, cardiovascular risk management, diabetes mellitus, clinical guidelines, quality of care, treatment goals, level of evidence
- MeSH terms
- Cardiovascular Diseases, Diabetes Mellitus, Humans, Risk Management, Societies, Medical, United States, Practice Guidelines as Topic, Diabetic Cardiomyopathies, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.